Diabetes Clinical Trial
Official title:
Diabetes Mellitus, Impaired Glucose Tolerance and Gestational Diabetes Mellitus Intervention Action-Leading Trial- Impaired Glucose Tolerance Study (DIGITAL-I Study)
The national epidemiological survey showed that the prevalence rate of pre-diabetes was up to
35.7% in China. Previous study indicated that lifestyle intervention in people with impaired
glucose tolerance could delay the onset of type 2 diabetes. However, patients with
pre-diabetes do not pay enough attention to their glucose metabolism, and most of them rarely
monitor their blood glucose. With the increasing use of smartphones, mobile applications
(APPs) can be applied in the education and management of chronic diseases, including
diabetes. Thus, the investigators will conduct a multi-centered, two-armed, open-labeled,
randomized controlled trial to evaluate whether the behavioral intervention by a mobile APP
can prevent the occurrence of diabetes in people with impaired glucose tolerance.
The investigators hypothesize that behavioral intervention in pre-diabetes with using a
mobile APP that incorporates nutrition, exercise and psychological support from trained
professional doctors will:
1. Reduce the risk of the onset of diabetes in people with impaired glucose tolerance.
2. Increase the reversal rate of becoming normal glucose tolerance and reduce the levels of
glycosylated hemoglobin in pre-diabetes.
Participants from fourteen research centers in the mainland of China will be recruited in the
study. People will be screened for a 75g oral glucose tolerance test (OGTT). The patients
whose fasting glucose between 6.1mmol/L and 7.0mmol/L or 2-hour value between 7.8mmol/L and
11.1mmol/L will be diagnosed with impaired glucose tolerance and recommended to participate
in the study.
People who meet the eligibility criteria and who are willing to provide informed consent will
be enrolled and randomized to behavioral intervention group and control group. People in the
behavioral intervention group will be educated and monitored by a mobile APP that provides
behavioral support including health knowledge education, mental health counseling, smart diet
advice, intelligent exercise guidance, and target weight management. Meanwhile, the
behavioral support will be modified by endocrinologists, dieticians, sports medicine
professionals and psychologists individually based on the feedback of their characteristics
and performance recorded in the APP. Participants randomized to the control group only have
regular care in their local hospitals.
Every three months, participants in the intervention group will be back to their research
centers and be collected with information including HbA1c levels, blood pressure, heart rate
tests, adverse events, combined medications and health checklists. Investigators conduct
face-to-face health education, lifestyle guidance and mobile APP software inspection. Every
one year, 75g OGTT (0min, 60min, 120min points of blood glucose and insulin levels), liver
and kidney function, blood lipids, glycosylated hemoglobin, urine routine and
electrocardiogram will be evaluated in both of the group. Investigators will compare the
diabetes risk in the two groups to evaluate whether behavioral intervention with a mobile APP
can reduce the risk of the onset of diabetes in people with impaired glucose tolerance.
Investigators also will compare the reversal rate of becoming normal glucose tolerance in
prediabetes and the changes of glycosylated hemoglobin levels in both groups. Behavioral
intervention with the APP will last for two years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05594446 -
Morphometric Study of the Legs and Feet of Diabetic Patients in Order to Collect Data Intended to be Used to Measure by Dynamometry the Pressures Exerted by Several Medical Compression Socks at the Level of the Forefoot
|
||
Completed |
NCT03975309 -
DHS MIND Metabolomics
|
||
Completed |
NCT01855399 -
Technologically Enhanced Coaching: A Program to Improve Diabetes Outcomes
|
N/A | |
Completed |
NCT01819129 -
Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes
|
Phase 3 | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Recruiting |
NCT05007990 -
Caregiving Networks Across Disease Context and the Life Course
|
||
Active, not recruiting |
NCT04420936 -
Pragmatic Research in Healthcare Settings to Improve Diabetes and Obesity Prevention and Care for Our Program
|
N/A | |
Recruiting |
NCT03549559 -
Imaging Histone Deacetylase in the Heart
|
N/A | |
Completed |
NCT04903496 -
Clinical Characteristics and Disease Burden of Diabetic Patients Based on Tianjin Regional Database
|
||
Completed |
NCT01437592 -
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
|
Phase 1 | |
Completed |
NCT01696266 -
An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
|
||
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT03390179 -
Hyperglycemic Response and Steroid Administration After Surgery (DexGlySurgery)
|
||
Not yet recruiting |
NCT05029804 -
Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes
|
N/A | |
Recruiting |
NCT05294822 -
Autologous Regenerative Islet Transplantation for Insulin-dependent Diabetes
|
N/A | |
Completed |
NCT04427982 -
Dance and Diabetes/Prediabetes Self-Management
|
N/A | |
Completed |
NCT02356848 -
STEP UP to Avert Amputation in Diabetes
|
N/A | |
Completed |
NCT03292185 -
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
|
Phase 1 | |
Active, not recruiting |
NCT05477368 -
Examining the Feasibility of Prolonged Ketone Supplement Drink Consumption in Adults With Type 2 Diabetes
|
N/A | |
Completed |
NCT04496401 -
PK Study in Diabetic Transplant récipients : From Twice-daily Tacrolimus to Once-daily Extended-release Tacrolimus
|
Phase 4 |